PATENT CLAIM ANALYSIS

Application Number: 15886640
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "094400"]

Abstract:
Disclosed herein are methods and compositions useful in the treatment and/or prevention of a disease or indication associated with accumulation of a bisretinoid, for example A2E. In many embodiments, the disclosed methods and compositions are useful in treating an eye disease, for example macular degeneration.

Claim (Index 4):
The composition of any of  claims 1 - 3 , wherein the interfering compound binds A2E or SapB at or near the SapB:A2E interface, and is selected from one or more of hydroxychloroquine (HCQ), chloroquine (CQ), atovaquone (ATO), apo-carotenal (ACar), Coenzyme Q4 (CoQ4), Coenzyme Q9 (CoQ9), Coenzyme (CoQ10), phosphatidylethanolamine(PEth), and phosphatidyl-choline (PCho).

Metadata:
- Claim Count in Document: 36.0
- Percentile: 88.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14398342', '13988754', '13980687', '12733631', '15118486']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7109876099819132
- 35 USC 102 Novelty (BERT): 0.524801982662539
- Combined Prediction Score: 0.6923690472499758
- Mean Citation Score: 266.98319000000004
- Max Citation Score: 295.7015
- Similarity Product: 195.6140438098312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test